Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

10:07am IST
Change (% chg)

Rs8.05 (+0.27%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for REDY.BO


Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)


Beta: 0.29
Market Cap(Mil.): Rs514,109.59
Shares Outstanding(Mil.): 170.63
Dividend: 20.00
Yield (%): 0.66


  REDY.BO Industry Sector
P/E (TTM): -- 36.30 36.51
EPS (TTM): -- -- --
ROI: -- 14.65 14.10
ROE: -- 15.54 15.11

BUZZ-India's Dr. Reddy's Labs falls on poor June-qtr results

** Shares of Dr. Reddy's Laboratories fall as much as 9.9 pct to lowest since May 16

27 Jul 2016

BUZZ-India's Dr. Reddy's Labs falls ahead of earnings

** Drugmaker Dr. Reddy's Laboratories Ltd falls as much as 3.75 pct in its biggest pct loss in nearly four months

25 Jul 2016

India's Dr Reddy's in $350 million deal to buy eight U.S. drugs from Teva, Allergan

MUMBAI India's second-largest drugmaker Dr Reddy's Laboratories Ltd said it agreed to buy eight generic drugs from Teva Pharmaceutical Industries and Allergan Plc for $350 million in cash to bolster its U.S. business.

11 Jun 2016

BUZZ-India's Dr Reddy's falls; U.S. agency charges firm for packaging lapses

** Drugmaker Dr.Reddy's Laboratories Ltd falls as much as 2.4 pct to its lowest since May 26

09 Jun 2016

MEDIA-US Agency charges India's Dr. Reddy's for packaging lapses; co disagrees - Economic Times

- Note: Reuters has not verified this story and does not vouch for its accuracy

09 Jun 2016

BRIEF-Spectrum Pharma says Dr Reddy's will be permitted to market generic version of Folotyn in US on Dec 1, 2022 or earlier

* Co's unit, dr. Reddy's labs, ltd entered into settlement agreement to resolve their patent litigation relating to folotyn

31 May 2016

India's Dr Reddy's falls on weak results, Deutsche Bank forecast cut

** India's second largest drugmaker on Thursday posted a near 86 pct slump in March-quarter profit

13 May 2016

BUZZ-India's Dr Reddy's rises on FDA approval for anti-nausea drug

** Dr Reddy's Laboratories rises as much as 3.5 pct, among top pct gainers on S&P BSE Healthcare index

03 Mar 2016

Earnings vs. Estimates